TY - JOUR T1 - A Pilot Study of High-Intensity Interval Training in Older Adults with Treatment Naïve Chronic Lymphocytic Leukemia JF - medRxiv DO - 10.1101/2021.07.06.21259279 SP - 2021.07.06.21259279 AU - Grace MacDonald AU - Andrea Sitlinger AU - Michael A. Deal AU - Erik D. Hanson AU - Stephanie Ferraro AU - Carl F. Pieper AU - J. Brice Weinberg AU - Danielle M. Brander AU - David B. Bartlett Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/07/2021.07.06.21259279.abstract N2 - Chronic lymphocytic leukemia (CLL) is the most common leukemia in the USA, affecting predominantly older adults. CLL is characterized by low physical fitness, reduced immunity, and increased risk of secondary malignancies and infections. One approach to improving physical fitness and immune functions is participation in a structured exercise program. The aims of this pilot study were to determine the feasibility and outcomes of 12-weeks of high-intensity interval training (HIIT) combined with muscle endurance-based resistance training on older adults with treatment naïve CLL. We enrolled eighteen participants with CLL aged 64.9 (9.1) years and assigned them to groups depending on distance lived from our fitness center. Ten participants (4M/6F) completed HIIT and six participants (4M/2F) completed a non-exercising control group (Controls). HIIT consisted of three 30-minute treadmill sessions/week plus two concurrent 30-minute strength training sessions/week. We confirmed feasibility if >70% of HIIT participants completed >75% of prescribed sessions and prescribed minutes, and if >80% of high-intensity intervals were at a heart rate corresponding to 80% of aerobic capacity [139 (19) bpm]. Other outcomes included aerobic capacity, muscle strength and endurance, and natural killer (NK) cell recognition and killing of tumor cells. Results are presented as Hedge’s G effect sizes (g), with 0.2, 0.5 and 0.8 representing small, medium and large effects, respectively. Feasibility was achieved, with HIIT completing 5.0 (0.2) sessions/week and 99 (3.6)% of prescribed minutes/week at 142 (19)bpm. Following HIIT, leg strength (g=2.52), chest strength (g=1.15) and seated row strength (g=3.07) were 35.4%, 56.1% and 39.5% higher, respectively, while aerobic capacity was 3.8% lower (g=0.49) than changes for Controls. Similarly, following HIIT, in vitro NK-cell cytolytic activity against the K562 cell line (g=1.43), OSU-CLL cell line (g=0.95), and autologous B-cells (g=1.30) were 20.3%, 3.0% and 14.6% higher, respectively, than changes for Controls. We demonstrate that 12-weeks of HIIT combined with muscle endurance-based resistance training is feasible in older adults with untreated CLL and that HIIT has a large effect on muscle strength and important components of immune function.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04950452Funding StatementThis work was supported by a Duke Claude D. Pepper Older Americans Independence Center Pilot Study Award (National Institutes of Health, National Institute on Aging P30-AG028716) and an American Society of Hematology Scholars Award, a National Institutes of Health, National Heart, Lung, and Blood Institute T32 grant (T32HL007057), and the Durham Veterans Affairs Medical Center Research Service.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Duke University Institutional Review Board (Pro00094597)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon reasonable request to the study teamB2Mβ2-microglobulinCDcluster of differentiationCLLChronic Lymphocytic LeukemiaCLL-IPIChronic Lymphocytic Leukemia – International Prognostic IndexCPETcardiopulmonary exercise testDMSODimethyl sulfoxideDPBSDulbecco’s phosphate buffered salineEBVEpstein Barr VirusEDTAEthylenediaminetetraacetic acidEREmergency RoomFBSfetal bovine serumFMOflow minus oneHIIThigh intensity interval trainingICAM-1Intercellular Adhesion Molecule 1IGHVimmunoglobulin heavy chain geneILinterleukinNK-cellNatural Killer CellPBSphosphate buffered salineOSU-CLLOhio State University-Chronic Lymphocytic LeukemiaPBMCperipheral blood mononuclear cellRPMIRoswell Park Memorial Institute MediumVO2peakestimated peak volume of oxygen consumption ER -